← Leaderboards
Barney Scott Graham
Niaid Extramural Activities
$0
Attributed
$0
Total exposure
0
Grants
0
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding mix
By agency
—
By mechanism
—
Top collaborators
No co-investigators on record.
Most similar at Niaid Extramural Activities
Same institution · by research overlap
Others in their field
Top investigators on “Human Subject”
- Sonia M Thomas · Research Triangle Institute$701,865,642
- Tracy L Nolen · Research Triangle Institute$474,487,152
- George R Seage · Abt Associates, Inc.$172,422,660
- Jay Arnold Tischfield · Rutgers, The State Univ Of N.J.$160,455,836
- Jeffrey P Krischer · University Of South Florida$155,493,283
- Charles A Coltman · Southwest Oncology Group$154,811,913
Research focus
Human SubjectPatient Oriented ResearchImmune ResponseClinical Trial Phase IVaccine DevelopmentLaboratory MouseRespiratory Syncytial VirusBioterrorism /Chemical WarfareVaccine EvaluationAids VaccinesVaccinesDosageHiv InfectionsFlow CytometryMedical Outreach /Case FindingCytotoxic T LymphocyteEnzyme Linked Immunosorbent AssayHuman TissueViral VaccinesInfectionVector VaccineCellular ImmunityTissue /Cell CultureResponse
Grant awards (80)
HIV Preventive Vaccine Studies$1,567,389
Z01 · FY2008 · AI · contact PI
Biodefense/Emerging Infection Vaccine Studies$969,286
Z01 · FY2008 · AI · contact PI
Sample Collection Protocols$655,788
Z01 · FY2008 · AI · contact PI
Cytolytic T Cell Activity In Response To Primary RSV Infection In Mice$625,552
Z01 · FY2008 · AI · contact PI
Factors Contributing To Immune-Enhanced Disease In The Pathogenesis of RSV$625,552
Z01 · FY2008 · AI · contact PI
Vaccine Studies in HIV-infected Subjects$408,379
Z01 · FY2008 · AI · contact PI
Vectors and Methods to Increase Immunogenicity during DNA Vaccination$408,379
Z01 · FY2008 · AI · contact PI
HIV Preventive Vaccine Studies$2,204,214
Z01 · FY2007 · AI · contact PI
Biodefense/Emerging Infection Vaccine Studies$1,574,438
Z01 · FY2007 · AI · contact PI
RSV and SARS Coronavirus Pathogenesis$775,000
Z01 · FY2007 · AI · contact PI
Cytolytic T Cell Activity In Response To Primary RSV Infection In Mice$775,000
Z01 · FY2007 · AI · contact PI
Factors Contributing To Immune-Enhanced Disease In The Pathogenesis of RSV$775,000
Z01 · FY2007 · AI · contact PI
Non B Clade HIV-1 Infections in African and African Immigrant Cohorts$314,888
Z01 · FY2007 · AI · contact PI
Interventions that Increase the DNA Uptake and Expression during DNA Vaccination$314,888
Z01 · FY2007 · AI · contact PI
Vaccine Studies in HIV-infected Subjects$314,888
Z01 · FY2007 · AI · contact PI
Sample Collection Protocols$314,888
Z01 · FY2007 · AI · contact PI
Vaccinia Vaccine Studies$314,888
Z01 · FY2007 · AI · contact PI
Non B Clade HIV-1 Infections in African and African Immi$0
Z01 · FY2006 · AI · contact PI
Advanced Development of a Prophylactic HIV Vaccine Prime$0
Z01 · FY2006 · AI · contact PI
Evaluation of Alternative Immunization Strategies For Sm$0
Z01 · FY2006 · AI · contact PI
Interventions that Increase the DNA Uptake and Expressio$0
Z01 · FY2006 · AI · contact PI
Vaccine Studies in HIV-infected Subjects$0
Z01 · FY2006 · AI · contact PI
Biodefense/Emerging Infection Vaccine Studies$0
Z01 · FY2006 · AI · contact PI
Sample Collection Protocols$0
Z01 · FY2006 · AI · contact PI
Vaccinia Vaccine Studies$0
Z01 · FY2006 · AI · contact PI
HIV Preventive Vaccine Studies$0
Z01 · FY2006 · AI · contact PI
RSV and SARS Coronavirus Pathogenesis$0
Z01 · FY2006 · AI · contact PI
Factors Contributing To Immune-Enhanced Disease In The P$0
Z01 · FY2006 · AI · contact PI
Production And Characterization Of HIV-1 Solid Phase Pro$0
Z01 · FY2006 · AI · contact PI
Alternative Immunization Strategies For Smallpox$0
Z01 · FY2005 · AI
Cytolytic T Cell Activity In Primary RSV Infection$0
Z01 · FY2005 · AI
Non B Clade HIV-1 Infections in African and African Immi$0
Z01 · FY2005 · AI
Factors Contributing To Immune-Enhanced Disease In The P$0
Z01 · FY2005 · AI
RSV and SARS Coronavirus Pathogenesis$0
Z01 · FY2005 · AI
HIV Preventive Vaccine Studies$0
Z01 · FY2005 · AI
Vaccinia Vaccine Studies$0
Z01 · FY2005 · AI
Sample Collection Protocols$0
Z01 · FY2005 · AI
Biodefense/Emerging Infection Vaccine Studies$0
Z01 · FY2005 · AI
Vaccine Studies in HIV-infected Subjects$0
Z01 · FY2005 · AI
DNA Uptake and Expression during DNA Vaccination$0
Z01 · FY2005 · AI
Cytolytic T Cell Activity In Response To RSV Infection$0
Z01 · FY2004 · AI
A Phase I Clinical Trial of an HIV-1 Multiclade Vaccine$0
Z01 · FY2004 · AI
A Phase I Clinical Trial of a Multiclade HIV-1 Vaccine$0
Z01 · FY2004 · AI
Alternative Immunization Strategies For Smallpox$0
Z01 · FY2004 · AI
Interventions that Increase the DNA Uptake &Expression$0
Z01 · FY2004 · AI
A Phase I Clinical Trial of a Multiclade HIV-1 Vaccine$0
Z01 · FY2004 · AI
Evaluation Of A Multicomponent Ebola Vaccine In Adults$0
Z01 · FY2004 · AI
Screening HIV-infected Subjects for Vaccine Research$0
Z01 · FY2004 · AI
Screening Subjects for Vaccine Research Studies$0
Z01 · FY2004 · AI
Specific Immune Responses In HIV-Infected and HIV-Uninfe$0
Z01 · FY2004 · AI
Phase I/II Clinical Trials Of Modified Vaccinia Virus An$0
Z01 · FY2004 · AI
Screening Subjects For Preventive HIV Vaccine Studies$0
Z01 · FY2004 · AI
RSV and SARS Coronavirus Pathogenesis$0
Z01 · FY2004 · AI
Phase I/II Clinical Trial of MVA in Vaccinia-Immune$0
Z01 · FY2004 · AI
Apheresis Procedures to Obtain Plasma or PBMCs$0
Z01 · FY2004 · AI
Factors Contributing To Immune-Enhanced Disease In RSV$0
Z01 · FY2004 · AI
NonBClade HIV1 Infection in African &African Immigrants$0
Z01 · FY2004 · AI
A Phase I Clinical Trial of a Multiclade HIV-1 DNA Plasm$0
Z01 · FY2003 · AI
Immunopathogenesis Of Hiv-1 Non-b Subtypes$0
Z01 · FY2003 · AI
Cytolytic T Cell Activity In Response To Primary Rsv Inf$0
Z01 · FY2003 · AI
Evaluation of Alternative Immunization Strategies For Sm$0
Z01 · FY2003 · AI
Interventions that Increase the DNA Uptake and Expressio$0
Z01 · FY2003 · AI
Factors Contributing To Immune-enhanced Disease In The P$0
Z01 · FY2003 · AI
A Phase I Clinical Trial to Evaluate a Multiple Strain E$0
Z01 · FY2003 · AI
Screening HIV-infected Subjects for Vaccine Research Stu$0
Z01 · FY2003 · AI
Screening Subjects for Vaccine Research Studies$0
Z01 · FY2003 · AI
Apheresis Procedures to Obtain Plasma or PBMCs for Resea$0
Z01 · FY2003 · AI
Phase I/II Clinical Trial of MVA in Vaccinia-Immune Indi$0
Z01 · FY2003 · AI
Specific Immune Responses To Hiv In Hiv-infected And Hiv$0
Z01 · FY2003 · AI
Phase I/ii Clinical Trials Of Modified Vaccinia Virus An$0
Z01 · FY2003 · AI
Screening Subjects For Hiv Vaccine Research Studies$0
Z01 · FY2003 · AI
The Role Of Rhoa In Rsv Pathogenesis And Morphogenesis$0
Z01 · FY2003 · AI
Cytolytic T Cell Activity In Response To Primary RSV Inf$0
Z01 · FY2002 · AI
Immunopathogenesis Of HIV-1 Non-B Subtypes$0
Z01 · FY2002 · AI
Immune-enhanced Disease In the Pathogenesis of RSV$0
Z01 · FY2002 · AI
Rhoa In RSV Pathogenesis And Morphogenesis$0
Z01 · FY2002 · AI
Screening Subjects For HIV Vaccine Research Studies$0
Z01 · FY2002 · AI
Phase I/II Clinical Trials Of Modified Vaccinia Virus An$0
Z01 · FY2002 · AI
Specific Immune Responses To HIV In HIV-infected And HIV$0
Z01 · FY2002 · AI
Evaluating a Multicomponent Ebola Vaccine In Adult Volun$0
Z01 · FY2002 · AI